Illinois Municipal Retirement Fund Increases Position in Krystal Biotech, Inc. $KRYS

Illinois Municipal Retirement Fund increased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,151 shares of the company’s stock after acquiring an additional 1,452 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Krystal Biotech were worth $3,655,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of KRYS. Greenline Wealth Management LLC purchased a new stake in Krystal Biotech in the 4th quarter worth approximately $34,000. Sound Income Strategies LLC lifted its stake in shares of Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares during the period. UMB Bank n.a. boosted its holdings in shares of Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares during the last quarter. Global Retirement Partners LLC boosted its holdings in shares of Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after purchasing an additional 142 shares during the last quarter. Finally, Danske Bank A S acquired a new stake in shares of Krystal Biotech during the third quarter worth $35,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $354.86 on Friday. The firm has a market capitalization of $10.46 billion, a price-to-earnings ratio of 47.44 and a beta of 0.50. Krystal Biotech, Inc. has a one year low of $130.50 and a one year high of $382.54. The company’s 50 day moving average price is $331.38 and its 200 day moving average price is $289.47.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Sell-side analysts forecast that Krystal Biotech, Inc. will post 7.41 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the transaction, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at approximately $347,270. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 26,642 shares of company stock worth $8,243,923. Insiders own 13.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on KRYS shares. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a research note on Tuesday, May 5th. Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Citigroup lifted their price target on Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. TD Cowen increased their price objective on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Finally, HC Wainwright raised their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Ten research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average target price of $360.67.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.